We are live on ! Find out more
UTMD icon

Utah Medical Products

110 hedge funds and large institutions have $161M invested in Utah Medical Products in 2024 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 43 increasing their positions, 26 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

111% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 9

65% more repeat investments, than reductions

Existing positions increased: 43 | Existing positions reduced: 26

10% more funds holding

Funds holding: 100110 (+10)

0.72% more ownership

Funds ownership: 68.49%69.21% (+0.72%)

0% less capital invested

Capital invested by funds: $162M → $161M (-$690K)

Holders
110
Holders Change
+10
Holders Change %
+10%
% of All Funds
1.58%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
19
Increased
43
Reduced
26
Closed
9
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Citadel Advisors
26
Citadel Advisors
Florida
$1.13M -$261K -3,849 -19%
RA
27
Royce & Associates
New York
$1.08M
Victory Capital Management
28
Victory Capital Management
Texas
$964K +$797K +11,735 +439%
LSV Asset Management
29
LSV Asset Management
Illinois
$925K
N
30
Nuveen
North Carolina
$848K
Ameriprise
31
Ameriprise
Minnesota
$807K +$506K +7,450 +162%
Connor, Clark & Lunn Investment Management (CC&L)
32
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$692K +$294K +4,330 +72%
Man Group
33
Man Group
United Kingdom
$679K +$58.7K +865 +9%
D.E. Shaw & Co
34
D.E. Shaw & Co
New York
$677K -$45.8K -674 -6%
Qube Research & Technologies (QRT)
35
Qube Research & Technologies (QRT)
United Kingdom
$651K +$279K +4,117 +73%
Charles Schwab
36
Charles Schwab
California
$644K -$815 -12 -0.1%
AQR Capital Management
37
AQR Capital Management
Connecticut
$594K +$117K +1,723 +24%
KPP
38
Kings Path Partners
Texas
$569K
American Century Companies
39
American Century Companies
Missouri
$501K -$301K -4,429 -37%
AI
40
Atria Investments
North Carolina
$481K -$4.21K -62 -0.9%
Goldman Sachs
41
Goldman Sachs
New York
$469K +$265K +3,898 +126%
RhumbLine Advisers
42
RhumbLine Advisers
Massachusetts
$445K +$77.2K +1,137 +21%
Envestnet Asset Management
43
Envestnet Asset Management
Illinois
$443K +$68.3K +1,006 +18%
GC
44
Globeflex Capital
California
$424K
Arrowstreet Capital
45
Arrowstreet Capital
Massachusetts
$396K +$402K +5,924 New
SA
46
Sanctuary Advisors
Indiana
$392K -$18.2K -268 -4%
SCP
47
Seizert Capital Partners
Michigan
$384K +$143K +2,112 +58%
Royal Bank of Canada
48
Royal Bank of Canada
Ontario, Canada
$382K +$194K +2,865 +102%
BCC
49
Bridge City Capital
Oregon
$352K
EHC
50
Everett Harris & Co
California
$350K -$188K -2,770 -35%

UTMD Hedge Fund Activity: Q3 2024 in Review

110 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Utah Medical Products (UTMD) for Q3 2024, worth a combined $161M — down 0.43% from $162M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new UTMD positions and 9 closed out — a net gain of 10 holders — while 43 added to existing stakes and 26 trimmed.

The largest buyer was Hotchkis & Wiley Capital Management, adding an estimated $3.4M. The largest seller was Fidelity Investments, cutting an estimated $9.89M.

  • 110 institutional investors held Utah Medical Products (UTMD) as of Q3 2024, up from 100 in Q2 2024.
  • Funds reported $161M of Utah Medical Products stock for Q3 2024, down 0.43% quarter-over-quarter.
  • 19 funds opened new Utah Medical Products positions in Q3 2024 and 9 closed out, a net change of +10 holders.
  • The largest Utah Medical Products buyer in Q3 2024 was Hotchkis & Wiley Capital Management, an estimated $3.4M added.
  • The largest Utah Medical Products seller in Q3 2024 was Fidelity Investments, an estimated $9.89M sold.

Based on aggregated 13F filings for Q3 2024.